Sinphar Pharmaceutical Co Ltd (1734) - Total Liabilities
Based on the latest financial reports, Sinphar Pharmaceutical Co Ltd (1734) has total liabilities worth NT$2.61 Billion TWD (≈ $82.31 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 1734 long-term investments to assets to see how much of total assets are deployed in long-term investments.
Sinphar Pharmaceutical Co Ltd - Total Liabilities Trend (2002–2025)
This chart illustrates how Sinphar Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Sinphar Pharmaceutical Co Ltd.
Sinphar Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Sinphar Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Columbus A/S
CO:COLUM
|
Denmark | Dkr540.64 Million |
|
AK Sigorta AS
IS:AKGRT
|
Turkey | TL22.70 Billion |
|
Krsnaa Diagnostics Limited
NSE:KRSNAA
|
India | Rs5.84 Billion |
|
Allpark Empreendimentos Participações e Serviços S.A
SA:ALPK3
|
Brazil | R$2.23 Billion |
|
SWK Holdings Corp
NASDAQ:SWKH
|
USA | $35.16 Million |
|
Ramada Investimentos e Industria S.A
LS:RAM
|
Portugal | €4.63 Million |
|
Tornado Global Hydrovacs Ltd
V:TGH
|
Canada | CA$64.04 Million |
|
Smec Co.Ltd
KQ:099440
|
Korea | ₩217.41 Billion |
Liability Composition Analysis (2002–2025)
This chart breaks down Sinphar Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Sinphar Pharmaceutical Co Ltd (1734) net asset quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.37 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.74 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sinphar Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sinphar Pharmaceutical Co Ltd (2002–2025)
The table below shows the annual total liabilities of Sinphar Pharmaceutical Co Ltd from 2002 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | NT$2.44 Billion ≈ $76.81 Million |
-11.42% |
| 2024-12-31 | NT$2.75 Billion ≈ $86.71 Million |
-3.54% |
| 2023-12-31 | NT$2.85 Billion ≈ $89.89 Million |
-3.88% |
| 2022-12-31 | NT$2.97 Billion ≈ $93.52 Million |
-5.58% |
| 2021-12-31 | NT$3.14 Billion ≈ $99.05 Million |
+5.39% |
| 2020-12-31 | NT$2.98 Billion ≈ $93.98 Million |
+9.93% |
| 2019-12-31 | NT$2.71 Billion ≈ $85.50 Million |
+10.52% |
| 2018-12-31 | NT$2.46 Billion ≈ $77.36 Million |
+1.61% |
| 2017-12-31 | NT$2.42 Billion ≈ $76.13 Million |
-0.33% |
| 2016-12-31 | NT$2.42 Billion ≈ $76.38 Million |
-0.08% |
| 2015-12-31 | NT$2.43 Billion ≈ $76.44 Million |
+1.71% |
| 2014-12-31 | NT$2.39 Billion ≈ $75.15 Million |
+7.96% |
| 2013-12-31 | NT$2.21 Billion ≈ $69.61 Million |
+19.74% |
| 2012-12-31 | NT$1.85 Billion ≈ $58.13 Million |
-6.71% |
| 2011-12-31 | NT$1.98 Billion ≈ $62.32 Million |
+27.41% |
| 2010-12-31 | NT$1.55 Billion ≈ $48.91 Million |
+4.13% |
| 2009-12-31 | NT$1.49 Billion ≈ $46.97 Million |
-18.01% |
| 2008-12-31 | NT$1.82 Billion ≈ $57.29 Million |
+24.14% |
| 2007-12-31 | NT$1.46 Billion ≈ $46.15 Million |
+31.83% |
| 2006-12-31 | NT$1.11 Billion ≈ $35.00 Million |
-7.00% |
| 2005-12-31 | NT$1.19 Billion ≈ $37.64 Million |
+15.96% |
| 2004-12-31 | NT$1.03 Billion ≈ $32.46 Million |
-7.83% |
| 2003-12-31 | NT$1.12 Billion ≈ $35.22 Million |
+43.92% |
| 2002-12-31 | NT$776.65 Million ≈ $24.47 Million |
-- |
About Sinphar Pharmaceutical Co Ltd
Sinphar Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the production, processing, selling, and trading of various medicines, Chinese medicines, medical cosmetic products and nutrients in Taiwan, Mainland China, Vietnam, Indonesia, and internationally. It operates through three segments: Pharmaceuticals, Healthy Food, and Others. The company offers pharmaceutical products, in… Read more